The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $676,789 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program to the Buck Institute for Research on Aging. The grant supports research to investigate the in vivo impact of N6-methyladenosine (m6A), a common mRNA modification, on synaptic function and neurotransmitter release. The research aims to establish critical roles for the epitranscriptome in normal synaptic activity, provide comprehensive genomic data on m6A targets and regulatory mechanisms, and define new ways m6A intersects with other neuronal pathways. The project period is from September 1, 2024 to August 31, 2025. As part of the project, the Buck Institute has issued a $122,674 sub-award to the Sloan-Kettering Institute for Cancer Research. The sub-recipient will be responsible for constructing and analyzing genomic datasets to elucidate the roles and functional impacts of the m6A regulatory pathway in the Drosophila nervous system, including m6A mapping, occupancy analysis, and transcriptome/translatome studies. They will also generate recombinant Drosophila strains to test cell-specific requirements and genetic dependencies for m6A regulation at the neuromuscular junction.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $154.7k | 9/23/24 | ||
| Not listed | $522.1k | 8/29/24 |
Grant Number | Description | Subgrantee | Prime Award | Dollars Obligated (Click to sort descending) | Updated At (Click to sort ascending) |
|---|---|---|---|---|---|
SUBPH101MSKCCS | Sloan-Kettering Institute For Cancer Research | Project Grant R56NS135053 | $199.3k | 2/12/25 |